CAJ | 학술논문

目的观察替吉奥(S-1)联合奥沙利铂(oxaliplatin,L-OHP)方案治疗晚期胃癌的近期疗效及毒性反应.方法23例均经病理组织学确诊为晚期胃腺癌,且手术不可切除或术后复发、转移胃癌.替吉奥80mg/m2/d,第1-14d,早晚饭后口服各1次;L-OHP130mg/m2加入5%葡萄糖液250ml中静脉滴注2h,第1 d,每3-4周为1个周期,完成2周期化疗后评价疗效及毒性反应.结果23例患者有1例CR(4.3%),12例PR(52.2%),6例SD(26.1%),4例PD(17.4%),有效率(CR+PR)56.5%,疾病控制率(CR+ PR+SD)82.6%.中位疾病进展时间(time to progression,TTP)5.8个月.毒副反应轻微,主要为胃肠道反应、骨髓抑制及外周神经毒性反应,但主要为Ⅰ-Ⅱ度.结论替吉奥联合奥沙利铂方案治疗晚期胃癌有较好疗效,毒副反应轻微,患者耐受性好,可作为晚期胃癌化疗方案临床应用推广.
목적관찰체길오(S-1)연합오사리박(oxaliplatin,L-OHP)방안치료만기위암적근기료효급독성반응.방법23례균경병리조직학학진위만기위선암,차수술불가절제혹술후복발、전이위암.체길오80mg/m2/d,제1-14d,조만반후구복각1차;L-OHP130mg/m2가입5%포도당액250ml중정맥적주2h,제1 d,매3-4주위1개주기,완성2주기화료후평개료효급독성반응.결과23례환자유1례CR(4.3%),12례PR(52.2%),6례SD(26.1%),4례PD(17.4%),유효솔(CR+PR)56.5%,질병공제솔(CR+ PR+SD)82.6%.중위질병진전시간(time to progression,TTP)5.8개월.독부반응경미,주요위위장도반응、골수억제급외주신경독성반응,단주요위Ⅰ-Ⅱ도.결론체길오연합오사리박방안치료만기위암유교호료효,독부반응경미,환자내수성호,가작위만기위암화료방안림상응용추엄.
Objective To evaluate the short term efficacy and toxicity of S-1 in combination with oxaliplatin in the patients with metastatic or recurrent gastric cancer. Methods 23 patients with metastatic or recurrent adenocarcinoma of the stomach were enrolled. S-1 was administered orally twice daily on days 1-14 at a dose of 80 mg/m2/day, and oxaliplatin was administered intravenously at a dose of 130 mg/m2 on day 1, repeated every three or four weeks. Efficacy and toxicity would be evaluated after the completion of two cycles of chemotherapy. Results Complete response was observed in 1 patients(4.3%), and partial remission was observed in 12 patients(52.2%), 6 patients achieved a stable status(26.1%), 4 patients suffered from progressive disease(17.4%). The total response rate(CR+PR) was 56.5% and the disease control rate(CR+PR+SD) was 82.6%. Median time to progression(TTP) was 5.8 months. Gastrointestinal reaction, peripheral nerve toxictity and hematological toxicities were the predominant toxicities. Most toxicities were Ⅰ/Ⅱ grade and mild. Conclusion The combination of S-1 and oxaliplatin as treament for patients with metastatic or recurrent gastric cancer was highly effective and well tolerated,which merits the further study in a prospective clinical trial.